

CITATION REPORT

List of articles citing

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

DOI: 10.1056/nejmoa055443

New England Journal of Medicine, 2006, 354, 1464-76.

Source: <https://exaly.com/paper-pdf/39708816/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1033	Antiplatelet therapy versus other antithrombotic strategies. 2001 , 367-385		
1032	Crystal structure of Enterobacter cloacae 908R class C beta-lactamase bound to iodo-acetamido-phenyl boronic acid, a transition-state analogue. 2003 , 60, 1764-73		18
1031	Retention of atherogenic lipoproteins in atherogenesis. 2004 , 61, 4-9		18
1030	Proteins interacting with the 26S proteasome. 2004 , 61, 1589-95		32
1029	Emerging roles of thioredoxin cycle enzymes in the central nervous system. 2005 , 62, 1063-80		84
1028	Therapy for patients with acute coronary syndromes--new opportunities. <i>New England Journal of Medicine</i> , 2006 , 354, 1524-7	59.2	5
1027	Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 663-77	3.8	9
1026	Coping with new challenges in acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2006 , 22 Suppl C, 13C-20C	3.8	
1025	Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. 2006 , 15, 843-55		77
1024	The year in non-ST-segment elevation acute coronary syndromes. 2006 , 48, 386-95		4
1023	OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?. 2006 , 3, 478-9		1
1022	Clinical efficacy and safety of fondaparinux: an emphasis on results in the elderly. 2006 , 2, 731-743		
1021	The status of new anticoagulants. 2006 , 134, 3-19		81
1020	Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. 2006 , 80, 691-702		20
1019	[Acute coronary syndrome with and without ST elevation]. 2006 , 31, 820-6		3
1018	Modern management of acute myocardial infarction. 2006 , 31, 769-817		11
1017	Abnormal haemoglobin levels in acute coronary syndromes. 2006 , 99, 851-62		19

1016	New anticoagulants. 2006 , 2006, 450-6		43
1015	Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients?. 2006 , 3, 358-9		0
1014	Vascular access site complications after PCI: current status and future directions. 2006 , 3, 402-3		6
1013	[Cardiology -- an update]. 2006 , 131, 1435-7		
1012	Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2006 , 354, 2830; author reply 2831-2	59.2	2
1011	Fondaparinux versus enoxaparin in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2006 , 354, 2829; author reply 2830	59.2	12
1010	The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy. 2006 , 114, 2313-6		11
1009	Think of HIT. 2006 , 2006, 408-14		65
1008	Bivalirudin for patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2006 , 355, 2203-16	59.2	1167
1007	Fondaparinux in patients with ST-segment elevation myocardial infarction. 2006 , 296, 2088; author reply 2088-9		
1006	Fondaparinux in patients with ST-segment elevation myocardial infarction. 2006 , 296, 2087; author reply 2088-9		
1005	Fondaparinux in patients with ST-segment elevation myocardial infarction. 2006 , 296, 2087-8; author reply 2088-9		
1004	Fondaparinux in Patients With ST-Segment Elevation Myocardial InfarctionâReply. 2006 , 296, 2087		
1003	Intensifying platelet inhibition--navigating between Scylla and Charybdis. <i>New England Journal of Medicine</i> , 2007 , 357, 2078-81	59.2	136
1002	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. 2007 , 28, 1193-204		216
1001	Abstracts of the 5th International Meeting on Intensive Cardiac Care, October 14-16, 2007, Tel Aviv, Israel. 2007 , 9, 134-74		
1000	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed		927
999	Predictive and protective factors associated with upper gastrointestinal bleeding after diovascular percutaneous coronary intervention: a case-control study. 2007 , 102, 2411-6		62

998	Use of newer anticoagulants in patients with chronic kidney disease. 2007 , 64, 2017-26	10
997	Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. 2007 , 7, 227-37	1
996	Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. 2007 , 5, 401-12	8
995	A replacement for warfarin: the search continues. 2007 , 116, 131-3	36
994	Review: New anticoagulants: a story of promise and disappointment. 2007 , 7, 51-58	1
993	Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. 2007 , 297, 591-602	226
992	Antagonists of activated factor X and thrombin: innovative antithrombotic agents. 2007 , 5, 121-8	3
991	Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm. 2007 , 28, 1273-4	290
990	Acute coronary syndromes without ST segment elevation. 2007 , 334, 1265-9	8
989	Pharmacological antithrombotic adjuncts to percutaneous coronary intervention. 2007 , 8, 759-76	1
988	Antithrombin treatment in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention. 2007 , 9, A11-A24	1
987	Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. 2007 , 167, 2423-30	55
986	Anticoagulant therapy in acute coronary syndromes. 2007 , 3, 301-8	
985	Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. 2007 , 167, 1539-44	55
984	Recombinant nematode anticoagulant protein c2 in non-ST segment elevation acute coronary syndrome and beyond. 2007 , 3, 365-75	3
983	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Nonâ€ST-Elevation Myocardial Infarction: Executive Summary. 2007 , 116, 803-877	158
982	Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions. 2007 , 297, 636-9	9
981	Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 2007 , 115, 2549-69	507

980	Managing acute coronary syndrome: evidence-based approaches. 2007 , 64, S14-24	5
979	Bleeding is bad.... isn't it?. 2007 , 116, 2776-8	9
978	Beyond unfractionated heparin and warfarin: current and future advances. 2007 , 116, 552-60	178
977	Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. 2007 , 116, 2793-801	182
976	Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. 2007 , 3, 345-64	6
975	Experimental model of lower limb ischemia in rats and the effect of YM466, an oral direct factor Xa inhibitor. 2007 , 30, 1874-7	2
974	Vena caval filters for the prevention of pulmonary embolism. 2007 , CD006212	8
973	Monitoring fondaparinux with the Sonoclot. 2007 , 18, 619-22	8
972	Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation. 2007 , 18, 97-103	22
971	Low molecular weight heparin and bleeding in patients with chronic renal failure. 2007 , 13, 409-13	43
970	Bivalirudin for Patients with Acute Coronary Syndromes. 2007 , 2007, 325-326	
969	Vena caval filters for the prevention of pulmonary embolism. 2007 , CD006212	8
968	Non-ST-segment elevation acute coronary syndromes: an algorithm for decision: reply. 2007 , 29, 280-281	
967	Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). 2007 , 153, 960-9	18
966	Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. 2007 , 154, 3-11	86
965	The "cardiac" literature in 2006: an annotated review for the emergency physician. 2007 , 25, 960-76	2
964	ACUITY-PCI: one drug does not fit all. 2007 , 369, 881-2	18
963	The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk. <i>Canadian Journal of Cardiology</i> , 2007 , 23, 663-71	3.8 22

962	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. 2007 , 28, 1598-660	1438
961	Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. 2007 , 28, 2077-86	143
960	Anticoagulants in heart disease: current status and perspectives. 2007 , 28, 880-913	94
959	Enoxaparin in acute coronary syndromes. 2007 , 5, 387-99	8
958	Perceived disability and lifestyle modification following hospitalization for non-ST elevation versus ST elevation acute coronary syndromes: the patients' point of view. 2007 , 6, 287-92	20
957	Anemia in patients undergoing percutaneous coronary intervention: current issues and future directions. 2007 , 7, 225-33	1
956	Management of non-ST-Segment Elevation Myocardial Infarction. 2007 , 91, 683-700; xi	2
955	Acute coronary syndromes: unstable angina/non-ST elevation myocardial infarction. 2007 , 23, 709-35, v	7
954	[Ischemic heart disease: 2006 update]. 2007 , 60 Suppl 1, 3-18	2
953	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. 2007 , 60, 1070.e1-1070.e80	14
952	[Therapeutic equivalence: concept and evidence levels]. 2007 , 129, 736-45	5
951	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Chest Physicians and Society for Cardiovascular Angiology and Intervention. 2007 , 135, 149-360	1412
950	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction—Executive Summary. 2007 , 50, 652-726	216
949	Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. 2007 , 49, 2398-407	63
948	The year in interventional cardiology. 2007 , 50, 270-85	6
947	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. 2007 , 50, 1742-51	203
946	Beyond heparin and warfarin: the new generation of anticoagulants. 2007 , 16, 271-82	57
945	Efficacy and safety of fondaparinux in patients with acute coronary syndromes. 2007 , 5, 1013-26	5

944 Myocardial Infarction: Risks and Hope. **2007**, 211-217

943 Diabetes and Acute Coronary Syndromes. 69-92

942 Acute Coronary Syndromes: Unstable Angina/Non-ST-Segment-Elevation Myocardial Infarction (NSTEMI ACS). 233-258

941 Non ST-Elevation Acute Coronary Syndromes. **2007**, 221-245

940 Guidelines for the management of acute coronary syndromes 2006. **2007**, 186, 101; discussion 101-2

939 Guidelines for the management of acute coronary syndromes 2006. **2007**, 186, 101-102

938 . **2007**, 3

937 . **2007**, 1

936 Catheter induced clot formation during angioplasty: an enoxaparin side effect?. **2007**, 70, 854-5

935 Myocardial infarction: contemporary management strategies. **2007**, 262, 59-77 12

934 Factor Xa or thrombin: is factor Xa a better target?. **2007**, 5 Suppl 1, 60-4 127

933 Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. **2007**, 5 Suppl 1, 255-63 64

932 A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. **2007**, 5, 1660-5 97

931 The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. **2007**, 100, 974-80 2

930 Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications. **2007**, 100, 1359-63 12

929 Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. **2007**, 100, 1376-82 12

928 [Contrast media and percutaneous coronary interventions]. **2007**, 56, 2-9 1

927 The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact. **2007**, 50, 167-80 0

926	The anticoagulated patient: strategies for effective blood loss management. 2007 , 142, S71-7	8
925	Anticoagulants and their reversal. 2007 , 21, 37-48	160
924	Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. 2007 , 30, II24-34	38
923	Issues in management of acute coronary syndromes: effects of bleeding. 2007 , 30, II1-3	
922	New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction. 2007 , 9, 289-97	3
921	Heparin resistance in acute coronary syndromes. 2007 , 23, 93-100	13
920	Frühe Antiplatelettherapie und Gerinnungshemmung bei akutem Koronarsyndrom. 2007 , 10, 500-510	
919	Advances in antithrombin and antiplatelet therapy for percutaneous coronary intervention. 2007 , 1, 284-289	
918	Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update. 2007 , 1, 303-309	
917	Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. 2008 , 1, 379-86	395
916	High-risk acute coronary syndrome patients with non-ST-elevation myocardial infarction: definition and treatment. 2008 , 22, 407-18	5
915	Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. 2008 , 26, 8-13	8
914	Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them?. 2008 , 26, 175-82	7
913	Acute coronary syndromes: management and secondary prevention. 2008 , 33, 25-37	6
912	Die Behandlung des akuten Koronarsyndroms ohne ST-Streckenelevation Neue Aspekte für die Koronarintervention. 2008 , 3, 71-77	1
911	Which heparin and how much?. 2008 , 10, 312-8	1
910	[Percutaneous coronary interventions (PCI)]. 2008 , 97, 513-47	47
909	Thrombophilies à l'héparine: est-ce la fin?. 2008 , 2008, 12-14	

908	2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 , 71, E1-40	23
907	2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice. 2008 , 51, 591-606	73
906	2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. 2008 , 52, 344-355.e1	39
905	Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 2008 , 21, 283-99	2
904	Individualized compared with conventional dosing of enoxaparin. 2008 , 83, 882-8	29
903	Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. 2008 , 11, 853-61	8
902	The editor's roundtable: management and treatment of non-ST-segment elevation in acute coronary syndromes. 2008 , 101, 1580-98	1
901	Impact of red blood cell transfusion on clinical outcomes in patients with acute myocardial infarction. 2008 , 102, 115-9	81
900	Efficacy and safety of fondaparinux and enoxaparin for acute coronary syndromes in CKD. 2008 , 51, 719-23	2
899	ACC/AHA Non-ST Elevation Myocardial Infarction Guidelines' Revision 2007: Implications for Nursing Practice. 2008 , 23, 53-56	
898	Contemporary approach to the diagnosis and management of non-ST-segment elevation acute coronary syndromes. 2008 , 50, 311-51	14
897	El registro MASCARA desenmascara la realidad asistencial del manejo de los síndromes coronarios agudos en España. 2008 , 61, 793-796	15
896	Major bleeding: management and risk reduction in acute coronary syndromes. 2008 , 9, 1869-83	8
895	Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 257S-298S	549
894	Spotlight on fondaparinux sodium in acute coronary syndromes. 2008 , 22, 413-5	1
893	The MASCARA Registry Reveals the True Nature of Acute Coronary Syndromes Treatment in Spain. 2008 , 61, 793-796	1
892	2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 , 51, 210-47	648
891	2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. 2008 , 51, 172-209	503

890	Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. 2008 , 51, 1734-41	64
889	Coronary intervention without a safety net. 2008 , 52, 1299-301	2
888	Anticoagulants in coronary artery disease. 2008 , 26, 615-28	5
887	Fondaparinux: use in thromboprophylaxis of acute medical patients. 2008 , 25, 81-8	4
886	Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. 2008 , 129, 379-87	54
885	The medical management of acute coronary syndromes and potential roles for new antithrombotic agents. 2008 , 34, 417-28	3
884	Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. 2008 , 155, 369-74	56
883	Noninvasive, medical management for non-ST-elevation acute coronary syndromes. 2008 , 155, 397-407	18
882	Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial. 2008 , 156, 769-75	16
881	Heparin: from animal organ extract to designer drug. <i>Thrombosis Research</i> , 2008 , 122, 753-62	8.2 43
880	Should radial artery access be the "gold standard" for PCI?. 2008 , 94, 1530-2	11
879	F?rmacos antitromb?ticos en el ?mbito extrahospitalario. 2008 , 10, 1493-1501	
878	Approaching an age of reason with antiplatelet therapy. 2008 , 371, 1315-6	7
877	Guidelines for anticoagulant use in acute coronary syndromes. 2008 , 371, 1559-61	12
876	Guidelines for anticoagulant use in acute coronary syndromes. 2008 , 372, 532-3; author reply 533-4	3
875	Guidelines for anticoagulant use in acute coronary syndromes âAuthors' reply. 2008 , 372, 533-534	1
874	Acute myocardial infarction. 2008 , 372, 570-84	466
873	2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. 2008 , 117, 261-95	520

872	Evidence-based performance and quality improvement in the acute cardiac care setting. 2008 , 24, 201-29, x	8
871	Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient. 2008 , 26, 145-55, v	13
870	Cost of care for new versus recurrent acute coronary syndrome patients. 2008 , 11, 81-99	8
869	Low-molecular-weight heparins : mechanisms, trials, and role in contemporary interventional medicine. 2008 , 8, 15-25	11
868	Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). 2008 , 94, 1019-25	324
867	2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. 2008 , 42, 989-1001	11
866	Will warfarin soon be pass? New approaches to stroke prevention in atrial fibrillation. 2008 , 52, 18-27	9
865	Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit. 2008 , 10, C1-C7	6
864	The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. 2008 , 29, 324-31	47
863	Incidence of bleeding in 'real-life' acute coronary syndrome patients treated with antithrombotic therapy. 2008 , 111, 41-6	11
862	Tailored antithrombotic therapy for acute coronary syndromes. 2008 , 6, 935-44	
861	Rivaroxaban: an oral direct inhibitor of factor Xa. 2008 , 65, 1520-9	58
860	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. 2009 , 30, 655-61	121
859	Anticoagulant Agents. 2008 , 195-232	
858	2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writ. 2008 , 117, 296-329	858
857	Do we need to adjudicate major clinical events? 2008 , 5, 56-60	97
856	Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. 2008 , 65, S22-8	4
855	Bias in AJHP supplements. 2008 , 65, 2328-9; author reply 2329-30; discussion 2330	1

854	Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease. 2008 ,		
853	Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm. 2008 , 94, 661-6		14
852	Immunogenicity of Biopharmaceuticals. 2008 ,		6
851	Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. 2008 , 29, 315-23		30
850	Is closure recommended for patent foramen ovale and cryptogenic stroke? Patent foramen ovale and cryptogenic stroke: to close or not to close? Closure: what else!. 2008 , 118, 1989-98		50
849	Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. 2008 , 118, 2038-46		76
848	Recent developments in acute coronary syndromes. 2008 , 8, 42-8		0
847	Is fondaparinux safer than enoxaparin for patients undergoing percutaneous coronary intervention?. 2008 , 5, 184-5		2
846	Antithrombotic therapy to support primary PCI. <i>New England Journal of Medicine</i> , 2008 , 358, 2280-2	59.2	12
845	The future of anticoagulation. 2008 , 29, 90-9		12
844	Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs. 2008 , 34, 762-71		3
843	Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome. 2008 , 9, 95-105		3
842	Benefits and risks with antiplatelet therapy: how great a problem is bleeding?. 2008 , 10, 119-124		7
841	The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes. 2008 , 10, C22-C29		4
840	Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 708S-775S		88
839	Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. 2008 , 111, 4871-9		208
838	Management of acute coronary syndrome. 2008 , 69, 324-9		
837	Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 670S-707S		123

836	Bivalirudin. 2008 , 99, 830-9	171
835	Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes. 2008 , 10, C14-C21	1
834	Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. 2008 , 10, C8-C13	7
833	Enoxaparin: a perspective on its use for coronary artery disease. 2008 , 4, 579-591	1
832	Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor. 2008 , 52, 66-71	16
831	In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. 2008 , 19, 279-84	10
830	The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. 2008 , 23, 327-34	14
829	Time to coronary angiography in patients with non-ST-segment elevation acute coronary syndrome: how fast should patients go to the catheterization laboratory?. 2008 , 23, 585-90	4
828	New anticoagulants. 2008 , 15, 509-15	33
827	Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit. 2008 , 7, 43-81	6
826	Management of non ST segment elevation acute coronary syndromes: A shift in the paradigm. 2008 , 121, 3-5	1
825	Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. 2008 , 4, 493-505	9
824	Fondaparinux. 2008 , 1-6	
823	Acute Coronary Syndromes and Acute Myocardial Infarction. 2008 , 589-646	
822	Antitrombóticos nas síndromes coronarianas agudas: diretrizes atuais e novas evidências. 2008 , 20,	
821	2007 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006. 2008 , 188, 302-3	27
820	Acute coronary syndromes and percutaneous coronary interventions. 2009 , 29, 381-387	8
819	The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. 2009 , 5, 693-704	14

818	Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. 2009 , 5, 677-91	
817	Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada. 2009 , 62, 367-74	2
816	Malignancy-Associated Thrombosis. 2009 , 24, 20-23	
815	Fondaparinux in acute coronary syndromes. 2009 , 5, 1615-23	3
814	Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. 2009 , 6, 239-51	84
813	Stopping the hemorrhage: a new baseline bleeding score brings us a step closer for patients with non-ST-elevation myocardial infarction. 2009 , 119, 1846-9	8
812	Pharmacotherapy of acute coronary syndrome: the ACUITY trial. 2009 , 10, 369-80	1
811	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. 2009 , 30, 1457-66	260
810	Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. 2009 , 120, 2006-11	64
809	New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?. 2009 , 30, 1695-702	13
808	Is there an acceptable ceiling for bleeding for an antithrombotic drug dose to be tested in a phase 3 trial?. 2009 , 30, 2556-7	
807	Acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 925; author reply 926-7	59.2 1
806	Leitfaden Herzkatheter. 2009 ,	2
805	Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. 2009 , 119, 1873-82	701
804	Avoiding and managing bleeding complications in patients with non-ST-segment elevation acute coronary syndromes. 2009 , 60, 148-58	1
803	Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). 2009 , 2, 330-8	40
802	Feasibility and safety of prehospital administration of bivalirudin in patients with ST-elevation myocardial infarction. 2009 , 103, 1635-40	23
801	Transradial intervention for minimizing bleeding complications in percutaneous coronary intervention. 2009 , 104, 55C-9C	22

800	Strategies to reduce bleeding among patients with ischemic heart disease treated with antiplatelet therapies. 2009 , 104, 60C-3C	9
799	Usefulness of fragmented QRS on a 12-lead electrocardiogram in acute coronary syndrome for predicting mortality. 2009 , 104, 1631-7	128
798	Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial. 2009 , 73, 319-25	15
797	Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes. 2009 , 74, 359-64	4
796	Early use of omeprazole benefits patients with acute myocardial infarction. 2009 , 28, 282-7	12
795	Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. 2009 , 28, 366-80	21
794	Kommentar zu den Leitlinien der European Society of Cardiology (ESC) zur Diagnose und Therapie des akuten Koronarsyndroms ohne ST-Strecken-Hebung (NSTEMI-ACS). 2009 , 3, 81-100	11
793	Favorable coagulation profile with fondaparinux after hip surgery in elderly patients. 2009 , 90, 476-482	2
792	Medical therapy in acute coronary syndromes: which medicines and at what doses?. 2009 , 11, 267-75	2
791	Transradial versus transfemoral approach for percutaneous coronary procedures. 2009 , 11, 391-7	15
790	[Costs caused by bleeds within the therapy of acute coronary syndromes in Germany]. 2009 , 34, 479-84	8
789	[Acute coronary syndromes without ST segment elevation]. 2009 , 34, 30-8	0
788	Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction. 2009 , 39, 103-9	5
787	New antithrombotic drugs. 2009 , 86, 139-46	77
786	Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. 2009 , 22, 266-73	16
785	The many costs of bleeding. 2009 , 22, 274-6	
784	Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelines. 2009 , 63, 642-55	4
783	Mechanism and predictors of failed transradial approach for percutaneous coronary interventions. 2009 , 2, 1057-64	129

782	The 80-lead ECG: more expensive NSTEMI or Occult STEMI. 2009 , 54, 789-90		
781	HORIZONS trial: a step forward for primary percutaneous coronary intervention. 2009 , 7, 125-9		1
780	Acute coronary syndromes: selective vs early invasive strategies. 2009 , 32, 621-6		1
779	Apixaban metabolism and pharmacokinetics after oral administration to humans. 2009 , 37, 74-81		479
778	Early versus delayed invasive intervention in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 360, 2165-75	59.2	578
777	Comparative metabolism of ¹⁴ C-labeled apixaban in mice, rats, rabbits, dogs, and humans. 2009 , 37, 1738-48		86
776	Treatment. 2009 , 146-217		
775	A new era for anticoagulants. 2009 , 20, 562-8		39
774	Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. 2009 , 157, 132-40		781
773	Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. 2009 , 157, 502-8		22
772	The pain and the gain of treating patients with acute coronary syndromes-can the two be separated?. 2009 , 157, 399-401		1
771	Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. 2009 , 157, 845-52		48
770	Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. 2009 , 158, 177-84		34
769	Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial. 2009 , 158, 726-33		4
768	Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). 2009 , 158, 713-8		48
767	The clinical significance of hematocrit values before and after percutaneous coronary intervention. 2009 , 158, 1024-30		21
766	Impact of computerized dosing on eptifibatide-associated bleeding and mortality. 2009 , 158, 1018-23		2
765	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. 2009 , 158, 881-886.e1		27

764	Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes. 2009 , 27, 595-606		1
763	Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention--an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. 2009 , 27, 726-8		2
762	Consensus of the French Society of Gerontology and Geriatrics and the French Society of Cardiology for the management of coronary artery disease in older adults. 2009 , 102, 829-45		13
761	Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 2009 , 53, 1021-30		106
760	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. 2009 , 54, 468-76		47
759	Antithrombotics in acute coronary syndromes. 2009 , 54, 969-84		44
758	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 1045-57	59.2	4753
757	Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. 2009 , 48, 1-22		404
756	Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes. 2009 , 43, 586-95		11
755	Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. 2009 , 7, 241-9		5
754	Drugs affecting blood coagulation, fibrinolysis, and hemostasis. 2009 , 31, 553-571		
753	Acute Coronary Syndromes: Diagnosis and Management, Part I. 2009 , 84, 917-938		244
752	Target populations and relevant therapeutic end points to further improve outcomes in NSTEMACS patients. 2009 , 5, 27-41		
751	Safety evaluation of enoxaparin in currently approved indications. 2009 , 8, 745-54		6
750	Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants. 2009 , 25, 413-20		17
749	Management of acute coronary syndromes in Mexico: gaps and opportunities to improve outcomes. 2009 , 9, 143-8		4
748	Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome. 2009 , 27, 585-95		10
747	Short Stay Management of Chest Pain. 2009 ,		

746	Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. 2009 , 373, 919-28	276
745	Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. 2009 , 374, 787-95	102
744	Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. 2009 , 374, 1149-59	308
743	The changing horizon of acute coronary syndrome. 2009 , 374, 1125-7	2
742	The right oral antithrombotics in acute coronary syndromes. 2009 , 374, 1947-8	10
741	Síndrome coronario agudo sin elevación del segmento ST. Evaluación inicial. Validación del diagnóstico y estratificación del riesgo. Tratamiento inicial. Estrategia invasiva. Modalidades de revascularización. 2009 , 10, 2465-2473	
740	Clinical implications and management of bleeding events in patients with acute coronary syndromes. 2009 , 10, 677-86	7
739	In-hospital outcomes of emergent and elective percutaneous coronary intervention in octogenarians. 2009 , 20, 118-23	9
738	The current role of anticoagulants in cardiovascular medicine. 2009 , 10, 595-604	13
737	Strategies to minimize bleeding complications of percutaneous coronary intervention. 2009 , 24, 273-8	8
736	Venous thromboembolism: pharmacological and nonpharmacological interventions. 2009 , 24, S8-13	4
735	Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. 2009 , 10, 616-23	16
734	Impact of bleeding complications on outcomes after percutaneous coronary interventions. 2009 , 1, 51-62	10
733	Unstable Angina and Non-ST-Elevation Myocardial Infarction. 2009 , 37-78	
732	New anticoagulants for atrial fibrillation. 2009 , 10, 446-53	3
731	Evaluating the need for a practical risk score to predict major bleeding in acute coronary syndromes. 2010 , 2, 757-759	
730	Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism. 2010 , 8, 5-11	4
729	Syndromes coronaires aigus. 2010 , 5, 1-21	

728	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines: Results From the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) Trial. 2010 , 2010, 69-72	
727	Vena caval filters for the prevention of pulmonary embolism. 2010 , CD006212	43
726	Practical implications of ACC/AHA 2007 guidelines for the management of unstable angina/non-ST elevation myocardial infarction. 2010 , 17, e24-40	6
725	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. 2010 , CD002130	16
724	Anticoagulation in percutaneous coronary intervention. 2010 , 2, 559-577	4
723	Anticoagulants. 2010 , 365-408	9
722	'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting. 2010 , 18, 444-50	5
721	Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. 2010 , 3, 358-65	28
720	Primary PCI for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. A case report and review of the literature. 2010 , 35, 43-9	19
719	Initiales Management des akuten Koronarsyndroms. 2010 , 13, 621-634	5
718	Antithrombotics in acute coronary syndromes: updates from the past year. 2010 , 12, 84-99	1
717	Pharmaka zur Thrombozyten- und Gerinnungshemmung in der Behandlung des akuten Koronarsyndroms. 2010 , 4, 239-248	0
716	What goes into a major acute coronary syndrome trial and what will future trials look like?. 2010 , 12, 348-55	2
715	Antiplatelet and anticoagulant therapies in acute coronary syndromes. 2010 , 24, 61-70	7
714	Practical strategies for the management of anticoagulation therapy: unsolved issues in the cardiac catheterization laboratory. 2010 , 24, 161-74	1
713	Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. 2010 , 24, 325-30	4
712	Frequency and safety of switching antithrombin therapy at a regional PCI center. 2010 , 29, 282-8	0
711	Update on heparin: what do we need to know?. 2010 , 29, 199-207	46

710	Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. 2010 , 29, 516-28	4
709	Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. 2010 , 30, 434-40	27
708	Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms?. 2010 , 30, 332-9	9
707	A clinical cardiology perspective of thrombophilias. 2010 , 30, 378-89	1
706	Nuevas evidencias y directrices en antiagregaci3n y anticoagulaci3n en s3ndrome coronario agudo e intervencionismo coronario percut3neo. 2010 , 10, 21C-29C	
705	Ischaemic heart disease: management of non-ST-elevation acute coronary syndrome. 2010 , 38, 424-430	
704	[Bleeding risk in ST-segment elevation myocardial infarction]. 2010 , 59, 356-61	1
703	Day 1 care in patients with non-ST-segment elevation myocardial infarction. 2010 , 11, 41-51	1
702	European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. 2010 , 81, 1353-63	54
701	European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. 2010 , 81, 1219-76	984
700	Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. 2010 , 81 Suppl 1, e175-212	39
699	Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). 2010 , 3, 1166-77	59
698	Noninferiority trial designs for odds ratios and risk differences. 2010 , 29, 982-93	15
697	Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. 2010 , 8, 641-50	11
696	Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectiveness. 2010 , 13 Suppl 1, S18-21	9
695	New aspects on treatment modalities for thromboembolic episodes. 2010 , 268, 109-19	2
694	Treatment Options in Acute Coronary Syndromes: Focus on Fondaparinux Sodium. 2010 , 2, CMT.S2197	
693	Anticoagulation. 2010 , 443-451	1

692	Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. 2010 , 6, 963-77	19
691	Reperfusion Therapies for Acute ST Segment Elevation Myocardial Infarction. 2010 , 110-144	
690	Anticoagulation after anterior myocardial infarction and the risk of stroke. 2010 , 5, e12150	15
689	The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro. 2010 , 103, 808-14	3
688	Impact of race and gender on antithrombotic therapy. 2010 , 104, 471-84	55
687	Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. 2010 , 6, 179-87	15
686	Medical Management of Unstable Angina and Non-àST Segment Elevation Myocardial Infarction. 2010 , 183-195	
685	Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. 2010 , 122, S422-65	74
684	Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. 2010 , 304, 1339-49	130
683	A 43-year-old man with angina, elevated troponin, and lateral ST depression: management of acute coronary syndromes. 2010 , 303, 54-63	
682	Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. 2010 , 39, 1567-81	22
681	Evaluating the Performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with non-ST-segment elevation acute myocardial infarction. 2010 , 121, 2118-24	49
680	Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials. 2010 , 7, 69-77	17
679	Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome. 2010 , 23, 324-34	1
678	Anticoagulant therapy for percutaneous coronary intervention. 2010 , 3, 80-8	63
677	Cardiovascular flashlight. Cleft bicuspid aortic valve: the Achilles' heel of echocardiography?. 2010 , 31, 2140	2
676	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. 2010 , 31, 2133-40	26
675	Advancing the care of cardiac patients using registry data: going where randomized clinical trials dare not. 2010 , 303, 2188-9	30

674	New anticoagulants. 2010 , 121, 1523-32	227
673	Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes. 2010 , 50, 904-13	4
672	Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery. 2010 , 44, 100-6	17
671	Fondaparinux for the treatment of superficial-vein thrombosis in the legs. <i>New England Journal of Medicine</i> , 2010 , 363, 1222-32	59.2 227
670	Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: balancing efficacy and bleeding risk. 2010 , 67, S7-17	3
669	Early management of unstable angina and non-ST-segment elevation myocardial infarction: summary of NICE guidance. 2010 , 96, 1662-8	28
668	Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. 2010 , 121, 750-8	412
667	Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. 2010 , 121, 43-51	100
666	Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. 2010 , 122, S787-817	191
665	Anticoagulation in the management of ST-segment elevation myocardial infarction. 2010 , 23, 335-43	
664	Issues in assessing and reducing the risk for venous thromboembolism. 2010 , 67, S9-16	3
663	Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome. 2010 , 12, D14-D23	1
662	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. 2010 , 31, 50-8	64
661	A reduction in bleeding in acute coronary syndromes? Let's not rain on the parade!. 2010 , 31, 640-1	2
660	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. 2010 , 31, 667-75	53
659	Aktuelle Aspekte der modernen interventionellen Koronartherapie. 2010 , 6, 317-334	
658	La profilassi della tromboembolia venosa nei pazienti con malattia renale cronica. 2010 , 4, 269-276	
657	Antithrombotic therapy in the elderly. 2010 , 56, 1683-92	98

656	Clinical pharmacology of direct and indirect factor Xa inhibitors. 2010 , 70, 2153-70	27
655	Hemorrhage in patients with acute coronary syndrome: from annoying observation to major challenge. 2010 , 63, 1-4	
654	Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. 2010 , 96, 1815-20	23
653	Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes. 2010 , 21, 254-9	8
652	Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an international randomized Evaluation (STEEPLE) trial. 2010 , 159, 110-6	25
651	Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience. 2010 , 159, 190-8	14
650	Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. 2010 , 160, 420-7	22
649	Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. 2010 , 160, 1000-7	16
648	Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. 2010 , 160, 1049-55	9
647	The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials. 2010 , 123, 103-10	4
646	A risk score to predict bleeding in patients with acute coronary syndromes. 2010 , 55, 2556-66	479
645	Hemorragia en pacientes con síndromes coronarios agudos: de un hallazgo molesto a un reto importante. 2010 , 63, 1-4	3
644	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. 2010 , 375, 283-93	531
643	Ticagrelor in ACS: redefining a new standard of care?. 2010 , 375, 263-5	14
642	[A new deal with new anticoagulants?]. 2010 , 35, 146-54	2
641	Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. 2010 , 121, 1713-21	18
640	Fondaparinux: does it cause HIT? Can it treat HIT?. 2010 , 3, 567-81	65
639	Prise en charge pharmacologique (antiagręants, anticoagulants) du syndrome coronarien aigu. 2010 , 19, 95-102	

638	Utilizaci3n de recursos en el manejo del sangrado en pacientes ingresados por s3ndrome coronario agudo. 2010 , 7, 176-186	2
637	Costs of bleeds relating to acute coronary syndrome therapies. 2010 , 13, 236-40	4
636	Fondaparinux: a pharmacoeconomic review of its use in the management of non-ST-segment elevation acute coronary syndrome. 2010 , 28, 687-98	4
635	Use of recombinant factor VIIa (NovoSeven(®)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. 2011 , 13, 93-8	22
634	Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. 2011 , 118, 6667-74	71
633	Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. 2011 , 57, 1445-54	42
632	Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. 2011 , 57, 253-69	662
631	2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 , 57, 1874-59	297
630	2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 , 57, 1874-59	338
629	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 , 58, 2550-2583	99
628	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 , 58, e44-122	1703
627	Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. 2011 , 58, 2263-9	40
626	Factor Xa inhibitors for acute coronary syndromes. 2011 , CD007038	6
625	The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). 2011 , 105, 760-2	24
624	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,	
623	Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. 2011 , CD007398	22
622	Enoxaparin: a pharmacologic and clinical review. 2011 , 12, 1157-70	23
621	Syndromes coronariens aigus : prise en charge th3rapeutique en urgence. 2011 , 1	1

620 Non-ST-Segment Elevations Myocardial Infarction. **2011**, 18-37

619	A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. 2011 , 161, 261-268.e1-2		29
618	Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. 2011 , 161, 254-260.e1-4		40
617	ED to catheterization laboratory: a roundtable integrating trials with practice. 2011 , 29, 1203-16		
616	Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS. <i>Canadian Journal of Cardiology</i> , 2011 , 27 Suppl A, S387-401	3.8	24
615	Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. 2011 , 62, 41-57		149
614	Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention. 2011 , 150, 79-83		12
613	[Reduction of haemorrhagic risk in acute coronary syndromes]. 2011 , 137, 650-5		
612	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 2011 , 32, 2999-3054		2614
611	Cardiovascular disease in the elderly. 2011 , 64, 697-712		45
610	Factor Xa and thrombin as targets for new oral anticoagulants. <i>Thrombosis Research</i> , 2011 , 127 Suppl 2, S5-S12	8.2	57
609	The quest for new anticoagulants: from clinical development to clinical practice. 2011 , 29, e12-22		8
608	Advances in cardiology: clinical trial update. 2011 , 7, 299-310		4
607	Cardiovascular Disease in the Elderly. 2011 , 64, 697-712		3
606	Tratamiento extrahospitalario y en Urgencias del síndrome coronario agudo sin elevación del segmento ST. 2011 , 10, 5903-5906		
605	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. 2011 , 377, 1409-20		1350
604	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. 2011 , 377, 2193-204		358
603	Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. 2011 , 378, 693-703		217

602	Intervenção coronária pelas vias radial ou femoral no infarto agudo do miocárdio com supradesnivelamento do segmento ST: uma visão da prática clínica contemporânea. 2011 , 19, 266-271	
601	Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention. 2011 , 7, 551-67	12
600	Emerging therapies for acute coronary syndromes. 2011 , 2, 61	2
599	Cardiac protection and pharmacologic management of myocardial ischemia. 1091-1105	
598	Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer?. 2011 , 26, 275-8	4
597	Adjunctive pharmacologic therapy in percutaneous coronary intervention: part II anticoagulant therapy. 2011 , 22, 113-21	
596	Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. 2011 , 112, 777-99	15
595	Treatment of acute coronary syndrome: Part 1: Non-ST-segment acute coronary syndrome. 2011 , 39, 2346-53	14
594	Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. 2011 , 22, 206-10	6
593	Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes. 2011 , 12, 1831-5	7
592	Bleeding avoidance strategies among patients undergoing percutaneous coronary intervention. 2011 , 3, 13-16	
591	Inhibitors of propagation of coagulation: factors V and X. 2011 , 72, 563-80	13
590	Pathological ankle-brachial index is equivalent of advanced age in acute coronary syndromes. 2011 , 41, 1268-74	9
589	Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial. 2011 , 9, 2159-67	6
588	Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable discussion. 2011 , 24, 119-36	2
587	¿Bivalirudina o heparina asociada a inhibidores de la glucoproteína IIb/IIIa en el síndrome coronario agudo sin elevación del ST?. 2011 , 11, 20-26	
586	Administración upstream de inhibidores de la glucoproteína IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: la estrategia TACTICS. 2011 , 11, 27-32	
585	Anticoagulant agents in acute coronary syndromes. 2011 , 36, 127-68	4

584	[Mortality of myocardial infarction]. 2011 , 60, 311-6	7
583	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2013 , 82, E266-355	81
582	Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?. 2011 , 19, 279-84	21
581	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, Sã Paulo, Brazil. 2011 , 32, 242-66	2
580	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. 2011 , 32, 378-85	10
579	[Therapy strategies for acute coronary syndrome and after coronary interventions. Antiplatelet agents and anticoagulants]. 2011 , 52, 1292-300	
578	Einsatz von neuen Antikoagulanzen bei kardiovaskulären Erkrankungen. 2011 , 5, 129-144	
577	Understanding equivalence and noninferiority testing. 2011 , 26, 192-6	453
576	How serious a problem is bleeding in patients with acute coronary syndromes?. 2011 , 13, 312-9	10
575	Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. 2011 , 9, 12	17
574	Comparison of procedural times, success rates, and safety between left versus right radial arterial access in primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 2011 , 78, 38-44	20
573	Transradial arterial access for coronary and peripheral procedures: executive summary by the Transradial Committee of the SCAI. 2011 , 78, 823-39	212
572	The time dependence of antithrombin initiation in patients with non-ST-segment elevation acute coronary syndromes: subgroup analysis from the ACUITY trial. 2011 , 57, 204-212.e1-6	1
571	Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. 2011 , 4, 191-7	182
570	The optimal pharmacological formula for percutaneous coronary intervention. 2011 , 12, 1075-86	
569	Future anticoagulants in interventional cardiology: anti-IXa and anti-Xa agents in percutaneous coronary intervention. 2011 , 7, 281-5	
568	Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. 2011 , 32, 205-17	510
567	Notfallbehandlung bei akutem Koronarsyndrom nach aktuellen Leitlinien. 2011 , 6, 65-80	

566	Rivaroxaban in the contemporary treatment of acute coronary syndromes. 2011 , 20, 849-57	3
565	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 , 123, 2022-60	267
564	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. 2011 , 123, 2736-47	2467
563	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 , 124, 2574-609	389
562	Anticoagulant Therapy in Acute Coronary Syndromes with Focus on Fondaparinux. 2011 ,	
561	Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). 2011 , 123, 2681-9	134
560	New anticoagulant agents in acute coronary syndromes. 2011 , 97, 244-52	13
559	Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinux. 2011 , 16, 72-3	1
558	The GRACE score's performance in predicting in-hospital and 1-year outcome. 2011 , 97, 1461-2	2
557	Almanac 2011: Acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology. 2011 , 97, 1820-7	3
556	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. 2011 , 32, 1854-64	273
555	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 , 123, e124-579	365
554	Risk factors and outcomes for patients with vascular disease and serious bleeding events. 2011 , 97, 1507-12	23
553	Is there a role for fondaparinux in perioperative bridging?. 2011 , 68, 36-42	5
552	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. 2011 , 16, 203-33	1
551	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 , 124, e574-651	1039
550	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. 2011 , 32, 1968-76, 1976a	42
549	Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. 2011 , 97, 887-91	15

548	Advances in antiplatelet therapy for acute coronary syndromes. 2012 , 88, 391-6	6
547	2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 2012 , 126, 875-910	382
546	Bleeding complications in patients with acute coronary syndromes: are they important and how can we prevent them?. 2012 , 40, 96-103	
545	2012 Oman Heart Association simplified guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. 2012 , 11, 139-46	3
544	Treatment algorithm in patients with NSTEMI and unstable angina. 2012 , 331-346	
543	Emerging anticoagulants. 2012 , 19, 3388-416	8
542	Pentasaccharide Derivatives. 2012 , 128-149	
541	Potential role of rivaroxaban in patients with acute coronary syndrome. 2012 , 6, 349-57	3
540	Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. 2012 , 125, 1414-23	14
539	Evaluating the bite of the BARC. 2012 , 125, 1344-6	7
538	Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. 2012 , 33, 51-60	49
537	The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. 2012 , 33, 2044-53	61
536	Treatment of acute coronary syndrome: part 2: ST-segment elevation myocardial infarction. 2012 , 40, 1939-45	8
535	Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. 2012 , 8, 239-49	9
534	Transradial Percutaneous Coronary Intervention in Patients with ST-Elevation Acute Myocardial Infarction. 2012 , 20, 282-287	1
533	Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. 2012 , 72, 177-82	15
532	Fondaparinux in Percutaneous Coronary Intervention for the Treatment of Acute Coronary Syndrome. 2012 , 20, 155-160	
531	Stratégie de prise en charge des syndromes coronariens aigus. 2012 , 7, 1-15	2

530	Invasive management of the acute coronary syndromes. 2012 , 4, 279-285	
529	Examining the appropriateness of radial or femoral access: evidence from the RIVAL trial and clinical practice. 2012 , 4, 675-687	1
528	Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. 2012 , 60, 2490-9	296
527	Epidemiology, diagnosis, treatment and management of superficial-vein thrombosis of the legs. 2012 , 25, 275-84	32
526	Role of antiischemic agents in the management of non-ST elevation acute coronary syndrome (NSTEMI-ACS). 2012 , 30, e16-22	3
525	Unfractionated heparin during elective PCI: fixed dose or weight adjusted?. 2012 , 30, 1-4	2
524	Assessing Bleeding Risk in Acute Coronary Syndromes. 2012 , 65, 4-6	1
523	Almanac 2011: Acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology. 2012 , 31, 179-188	
522	Risque résiduel post-SCA et place des traitements anti-thrombotiques. 2012 , 2012, 16-17	
521	Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome. 2012 , 8, 1483-93	1
520	[Contribution of the new oral anticoagulants to the treatment of acute coronary syndrome]. 2012 , 139 Suppl 2, 41-5	
519	Women and the management of acute coronary syndrome. 2012 , 90, 1151-9	13
518	Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. 2012 , 1, 222-31	53
517	Bivalirudin in acute myocardial infarction: NICE guidance. 2012 , 98, 435-7	5
516	Assessing bleeding risk in acute coronary syndromes. 2012 , 65, 4-6	11
515	Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. 2012 , 65, 173.e1-173.e55	15
514	Fondaparinux - data on efficacy and safety in special situations. <i>Thrombosis Research</i> , 2012 , 129, 407-17	8.2 68
513	Old and new heparins. <i>Thrombosis Research</i> , 2012 , 129, 388-91	8.2 25

512	Oral direct factor Xa inhibitors. 2012 , 111, 1069-78	78
511	Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials. 2012 , 155, 243-8	3
510	Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. 2012 , 8, 4092-100	58
509	The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review. 2012 , 22, 645-61	11
508	Oral factor Xa inhibitors for the long-term management of ACS. 2012 , 9, 392-401	5
507	Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. 2012 , 10, 489-503	10
506	Acute Coronary Syndromes (ST Elevation and Non-ST Elevation). 2012 , 86-116	
505	Les anti-agrégants plaquettaires dans les syndromes coronaires aigus : rapport bénéfice/risque. 2012 , 4, 217-222	
504	Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned	16
503	2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 , 60, 645-81	450
502	Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REGistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry. 2012 , 5, 23-35	90
501	Transradial versus transfemoral artery approach for coronary angiography and percutaneous coronary intervention in the extremely obese. 2012 , 5, 819-26	58
500	Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. 2012 , 5, 958-65	64
499	Drug-drug interactions in cardiovascular catheterizations and interventions. 2012 , 5, 1195-208	11
498	Heparin in the prophylaxis and treatment of venous thromboembolism and other thrombotic diseases. 2012 , 179-209	8
497	Almanac 2011: acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology. 2012 , 31, 179-88	
496	Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. 2012 , 98, 303-11	116
495	Günstigere Langzeitergebnisse mit früher interventioneller Therapie. 2012 , 15, 10-14	

494	Cost effectiveness of anticoagulation in acute coronary syndromes. 2012 , 30, 303-21	6
493	Sex and Gender Differences in Pharmacology. 2012 ,	26
492	Fondaparinux and acute coronary syndrome. 2012 , 7, 545-548	1
491	Acute Coronary Syndrome. 2012 , 425-434	
490	36 Antikoagulanzen. 2012 ,	
489	ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE. 2012 , 8, 531-537	
488	Causality analysis of the relationship between bleeding and lethality in Acute Coronary Syndromes. 2012 , 98, 488-96	1
487	Is the warfarin saga over?. 2012 , 42, 51-5	3
486	The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. 2012 , 8, 371-82	31
485	Antithrombotic therapy in patients with chronic kidney disease. 2012 , 125, 2649-61	92
484	Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT study. 2012 , 79, 823-33	9
483	Rapid cycle change to predominantly radial access coronary angiography and percutaneous coronary intervention: effect on vascular access site complications. 2012 , 79, 589-94	10
482	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2012 , 79, 453-95	121
481	Novel oral anticoagulants after acute coronary syndromes. 2012 , 26, 265-71	
480	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. 2012 , 34, 143-63	
479	Modern management of acute myocardial infarction. 2012 , 37, 237-310	12
478	Almanac 2011: Acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology. 2012 , 64, 39-49	
477	Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. 2012 , 271, 521-36	16

476	Promise of factor Xa inhibition in acute coronary syndromes. 2012 , 14, 40-8	2
475	Antithrombotic pharmacotherapy in the elderly: general issues and clinical conundrums. 2012 , 14, 57-68	2
474	Routine invasive versus conservative management strategies in acute coronary syndrome: time for a "hybrid" approach. 2012 , 5, 30-40	4
473	Risk stratification in acute coronary syndromes. 2012 , 5, 1-10	2
472	Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction. 2013 , 81, E9-14	6
471	Arteriovenous fistula as a complication of transradial coronary angiography: a case report. 2013 , 7, 21	10
470	New developments in parenteral anticoagulation for arterial and venous thromboembolism. 2013 , 26, 203-13	8
469	Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndrome. 2013 , 15, 386	13
468	Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. 2013 , 36, 115-30	
467	Stroke Prevention in Atrial Fibrillation. 2013 , 1, 98-104	
466	Treatment of NSTEMI (Non-ST Elevation Myocardial Infarction). 2013 , 1, 18-28	0
465	Akute koronare Syndrome. 2013 , 18, 231-240	
464	Basics of Antithrombotic Therapy for Cardiovascular Disease: Pharmacologic Targets of Platelet Inhibitors and Anticoagulants. 2013 , 2, 499-513	1
463	Antiplatelet and Anticoagulation Therapy. 2013 ,	
462	Design and rationale of the AngioSeal versus the Radial approach In acute coronary Syndrome (ARISE) trial: a randomized comparison of a vascular closure device versus the radial approach to prevent vascular access site complications in non-ST-segment elevation acute coronary syndrome patients. 2013 , 14, 435	13
461	Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention. 2013 , 73, 1921-33	15
460	[Reversal for heparins and new anticoagulant treatments]. 2013 , 32, 37-49	6
459	A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). 2013 , 112, 1367-72	40

- 458 Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III). **2013**, 26, 107-13 26
- 457 Current and Future Options for Anticoagulant Therapy in the Acute Management of ACS. **2013**, 15, 21-32
- 456 Non-ST-Segment Elevation Acute Coronary Syndromes. **2013**, 153-177
- 455 Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk. **2013**, 163, 5-18 15
- 454 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **2013**, 61, e179-347 328
- 453 Novel antiplatelet and anticoagulant agents in the cardiac care unit. **2013**, 31, 533-44, viii 4
- 452 Combination Antithrombotic Management for Non-ST Segment Elevation Acute Coronary Syndromes. **2013**, 2, 553-571
- 451 Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. **2013**, 165, 644-54, 654.e1 8
- 450 Monitoring and Reversal of Anticoagulation and Antiplatelets. **2013**, 2, 643-663 1
- 449 F. **2013**, 269-301
- 448 Novel anti-thrombotic therapy in acute coronary syndromes. **2013**, 55, e117-e125
- 447 Management of coronary atherosclerosis and acute coronary syndromes in patients with chronic kidney disease. **2013**, 38, 165-206 9
- 446 Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013. **2013**, 9, 371-85
- 445 Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes). **2013**, 439-457
- 444 Antithrombotic Treatment of Cardiovascular Disease. **2013**, 143-173
- 443 Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. **2013**, 13, 233-50 35
- 442 Akute koronare Syndrome. **2013**, 16, 141-151
- 441 Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. **2013**, CD002130 12

440	A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 2013 , 34, 2481-9	70
439	2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 , 127, e663-828	193
438	Pharmacologic Options for Treatment of Ischemic Disease. 2013 , 83-130	4
437	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. 2013 , 34, 894-902d	20
436	Fondaparinux. 2013 , 30, 172-173a	
435	How to reduce mortality in ST-elevation myocardial infarction patients treated with primary percutaneous coronary interventions: cut the bleeding. 2013 , 29, 189-94	7
434	Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. 2013 , 109, 769-86	31
433	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. 2013 , CD002130	7
432	High platelet reactivity--the challenge of prolonged anticoagulation therapy after ACS. 2013 , 109, 799-807	5
431	Prevention of venous thromboembolism in hospitalized patients with chronic kidney disease. 2013 , 269-276	
430	Contemporary themes in acute coronary syndrome management: from acute illness to secondary prevention. 2013 , 199, 174-8	12
429	Fondaparinux. 2013 , 44-52	
428	The impact of vascular access for in-hospital major bleeding in patients with acute coronary syndrome at moderate- to very high-bleeding risk. 2013 , 28, 1307-15	6
427	Hemostatic Aspects of Cardiovascular Medicine. 2013 , 342-394	
426	Thrombosis - Besieged but Poorly Understood. 2014 , 1, 4	
425	Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention. 2014 , 44, 82-8	9
424	Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. 2014 , 112, 79-86	11
423	Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. 2014 , 6, 260ra150	52

422	Hemostasis and Anticoagulants. 2014 , 479-496	2
421	Comparative evaluation of efficacy, safety and haemostatic parameters of enoxaparin and fondaparinux in unstable coronary artery disease. 2014 , 8, 31-4	3
420	Barking up the right tree at last: another step closer to a universal definition of bleeding. 2014 , 35, 2507-9	1
419	[Antithrombotic treatment in acute coronary syndrome]. 2014 , 139 Suppl 1, S17-22	
418	PK evaluation of fondaparinux sodium for the treatment of thrombosis. 2014 , 10, 269-77	2
417	[From heparin to apixaban: anticoagulants cut both ways?]. 2014 , 139, 89-97	0
416	Oral anticoagulants for Asian patients with atrial fibrillation. 2014 , 11, 290-303	27
415	Rivaroxaban in acute coronary syndromes--is it prime time?. 2014 , 12, 649-58	1
414	Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. 2014 , 168, 838-45.e6	38
413	Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications. 2014 , 171, 541-54	54
412	Role of oral factor Xa inhibitors after acute coronary syndrome. 2014 , 129, 224-32	6
411	Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 2014 , 349, g6419	36
410	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 130, e344-426	754
409	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 130, 2354-94	696
408	Treatment of NSTEMI Patients. 2014 , 86-90	
407	[Antiplatelet therapy and anticoagulation in acute coronary syndrome: current evidence]. 2014 , 39, 692-701	0
406	Anticoagulation and antiplatelet therapy in acute coronary syndromes. 2014 , 81, 103-14	6
405	Pharmacological effects and clinical applications of ultra low molecular weight heparins. 2014 , 8, 1-10	19

404 Acute Coronary Syndrome. **2014**, 49-66

403 In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis. **2014**, 37, 118-30 5

402 Keine ausreichende Wirksamkeit von Dabigatran bei Patienten mit Kunstklappen. **2014**, 8, 117-119

401 Akutversorgung des akuten Myokardinfarktes. **2014**, 8, 72-77 2

400 Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease. **2014**, 7, 112-25

399 Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) trial. **2014**, 7, 101-11 38

398 A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention. **2014**, 32, 377-93 4

397 Pharmacological Treatment of Acute Coronary Syndromes. **2014**, 1

396 Optimal anticoagulation duration of unfractionated and low molecular weight heparin in non-ST elevation acute coronary syndrome: a systematic review of the literature. **2014**, 177, 461-6 9

395 Strategia di gestione delle sindromi coronariche acute. **2014**, 18, 1-14

394 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. **2014**, 64, 2645-2687 132

393 Ischaemic heart disease: management of non-ST-elevation acute coronary syndrome. **2014**, 42, 505-511

392 Evaluaci3n del puntaje de sangrado âRUSADEâ como prueba diagn3stica para determinar sangrado mayor en pacientes con s3ndrome coronario agudo sin elevaci3n del ST. **2014**, 21, 13-23 2

391 Acute coronary syndromes: unstable angina and non-ST elevation myocardial infarction. **2014**, 32, 353-70 3

390 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). **2014**, 35, 2541-619 3467

389 Cost effectiveness of treatments for non-ST-segment elevation acute coronary syndrome. **2014**, 32, 1063-78 1

388 Management of Acute Coronary Syndrome. **2014**, 238-266

387 Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. **2014**, 64, 1270-80 46

386	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 64, e139-e228	1822
385	Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: randomised comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting through the femoral approach. rationale and design. 2014 , 28, 273-9	8
384	Recent advances in antithrombotic therapy after acute coronary syndrome. 2014 , 186, 589-96	3
383	A quantitative perspective on ethics in large team science. 2014 , 20, 923-45	21
382	Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?. 2014 , 168, 611-21	29
381	Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials. 2014 , 167, 401-412.e6	19
380	Antiplatelet and anticoagulation therapy for acute coronary syndromes. 2014 , 114, 1929-43	58
379	Potential antidotes for reversal of old and new oral anticoagulants. <i>Thrombosis Research</i> , 2014 , 133 Suppl 2, S158-66	8.2 35
378	Update: acute coronary syndromes (VI): treatment of acute coronary syndromes in the elderly and in patients with comorbidities. 2014 , 67, 564-73	9
377	El tratamiento de síndromes coronarios agudos de ancianos y pacientes con comorbilidades. 2014 , 67, 564-573	24
376	Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis. 2014 , 9, e90986	5
375	Femoral micropuncture or routine introducer study (FEMORIS). 2014 , 129, 39-43	23
374	Management of Thrombotic Disorders. 2014 , 27-40	
373	Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory. 2014 , 22, 7	2
372	Perspectives: Direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. 2014 , 16, A56-A60	9
371	Ten clinician-driven strategies for maximising value of Australian health care. 2014 , 38, 125-33	11
370	Validación de la escala CRUSADE para evaluar el riesgo de sangrado en pacientes con infarto agudo de miocardio sin elevación del ST. 2015 , 22, 169-178	
369	Identificação de pacientes com risco de complicações do acesso vascular. 2015 , 23, 236-237	

368	Identifying patients at risk of vascular access complications. 2015 , 23, 236-237	
367	Comparative studies on biological activity of generic and branded enoxaparin in vivo and vitro. 2015 , 26, 805-10	2
366	Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5). 2015 , 15, 180	6
365	Fondaparinux vs. enoxaparin in patients with non-ST elevation acute coronary syndromes (NSTEMI-ACS) treated with percutaneous coronary intervention and tirofiban: an exploratory study in China. 2015 , 40, 584-589	6
364	Acute management of unstable angina and non-ST segment elevation myocardial infarction. 2015 , 13, 454-61	7
363	14 Specific Anticoagulant and Antiplatelet Agent Reversal Strategies for Neurosurgical Patients. 2015 ,	
362	Developments and risk analysis in anticoagulation. 2015 , 10, 66-73	1
361	Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review. 2015 , 15, 415-27	8
360	Medical Treatment of Unstable Angina and Acute Non-ST-Elevation Myocardial Infarction. 2015 , 461-504	0
359	Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention. 2015 , 38, 481-91	6
358	Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand. 2015 , 24, 860-8	5
357	Das initiale Management des akuten Koronarsyndroms. 2015 , 18, 984-1002	3
356	A 35-year journey to evidence-based medicine: a personal story. 2015 , 36, 3460-6	2
355	Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST. 2015 , 68, 1125.e1-1125.e64	20
354	Temporal Trends and Outcomes Associated with Major Bleeding in Acute Coronary Syndromes: A Decade-Long Perspective from the Acute Coronary Syndrome Israeli Surveys 2000-2010. 2015 , 132, 163-71	7
353	Guía de práctica clínica de la ESC sobre revascularización miocárdica, 2014. 2015 , 68, 144.e1-144.e95	1
352	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. 2015 , 169, 531-8	6
351	Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. 2015 , 313, 707-16	24

350	Access site practice and procedural outcomes in relation to clinical presentation in 439,947 patients undergoing percutaneous coronary intervention in the United Kingdom. 2015 , 8, 20-9	95
349	Frequency and predictors of thrombus inside the guiding catheter during interventional procedures: an optical coherence tomography study. 2015 , 31, 239-46	3
348	Management of the patient with an acute coronary syndrome using oral anticoagulation. 2015 , 23, 407-14	3
347	Coronary intervention: radial artery access comes of age. 2015 , 385, 2437-9	11
346	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. 2015 , 36, 3238-49	129
345	Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. 2015 , 29, 335-43	18
344	How to balance risks and benefits in the management of CKD patients with coronary artery disease. 2015 , 28, 403-13	13
343	Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. 2015 , 131, 1123-49	41
342	Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. 2015 , CD007398	58
341	A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients. 2015 , 4, 95-116	10
340	European Resuscitation Council Guidelines for Resuscitation 2015 Section 8. Initial management of acute coronary syndromes. 2015 , 95, 264-77	56
339	Traitement médicamenteux du syndrome coronarien aigu du sujet âgé. 2015 , 2015, 8-11	
338	[Acute coronary syndrome]. 2015 , 140, 97-103	0
337	Acute coronary syndromes. 2015 , 351, h5153	28
336	Akute koronare Syndrome. 2015 , 12, 7-16	
335	Coronary artery disease in the military patient. 2015 , 161, 211-22	5
334	HAS-BLED score predicts risk of in-hospital major bleeding in patients with acute non-ST segment elevation myocardial infarction. <i>Thrombosis Research</i> , 2015 , 136, 775-80	8.2 8
333	Therapy for Acute Coronary Syndrome and Unstable Angina. 2015 , 467-493	

332	Acute coronary syndrome. 2015 , 30, 186-200	60
331	Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. 2015 , 4, 211-9	4
330	THE USE OF ENOXAPARIN IN ACUTE CORONARY SYNDROME. 2016 , 12, 749-757	
329	Treatment. 145-216	1
328	New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. 2016 , 21, 284	2
327	Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data. 2016 , 107, 239-244	3
326	Heparins. 2016 , 673-695	
325	Antiplatelet and Anticoagulation Treatment in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Comparison of the Updated North American and European Guidelines. 2016 , 24, 170-6	2
324	Management of Patients With NSTEMI-ACS: A Comparison of the Recent AHA/ACC and ESC Guidelines. 2016 , 68, 313-321	40
323	Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. 2016 , 9, 1419-34	253
322	PCI Strategies in Acute Coronary Syndromes without ST Segment Elevation (NSTEMACS). 2016 , 148-154	
321	Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease. 2016 , 377-388	
320	Parenteral Anticoagulant Agents in PCI. 2016 , 408-414	
319	The Optimal Duration of Dual Antiplatelet Therapy After PCI. 2016 , 436-442	
318	Monitoring and Reversal of Anticoagulation and Antiplatelet Agents. 2016 , 469-483	
317	Cardiovascular Medicine. 2016 , 282-298	
316	Anticoagulant therapy for non-ST-segment elevation acute coronary syndrome in China: A multi-center observational study. 2016 , 4, 25-28	4
315	Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. 2016 , 102, 1883-1889	37

314	Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates. 2016 , 3, MR000043		21
313	Interpreting Geographic Variations in Results of Randomized, Controlled Trials. <i>New England Journal of Medicine</i> , 2016 , 375, 2263-2271	59.2	50
312	Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban. 2016 , 3, 13		2
311	Antiplatelet versus oral anticoagulant therapy as antithrombotic prophylaxis after mitral valve repair. 2016 , 151, 1302-8.e1		11
310	Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 2016 , 102, 882-92		1
309	2014 PHA Clinical Practice Guidelines for the Diagnosis and Management of Patients with Coronary Heart Disease. 2016 , 24,		4
308	Optimisation of antithrombotic therapy in patients with acute coronary syndrome to reduce bleeding episodes. 2016 , 70, 156-62		2
307	Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis. 2016 , 31, 275-87		3
306	Reperfusion Therapy for Acute Myocardial Infarction. 2016 ,		
305	New Therapeutic Agents in Thrombosis and Thrombolysis. 2016 ,		6
304	Mechanical Reperfusion for STEMI. 2016 ,		
303	Comparison between Fondaparinux and Low-Molecular-Weight Heparin in Patients with Acute Coronary Syndrome: A Meta-Analysis. 2016 , 133, 163-72		13
302	Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association. 2016 , 133, 916-47		572
301	Individualized approaches to thromboprophylaxis in atrial fibrillation. 2016 , 173, 143-58		9
300	A Central Role for Monocyte-Platelet Interactions in Heart Failure. 2016 , 21, 245-61		12
299	Acute Coronary Syndromes: Unstable Angina and Non-ST Elevation Myocardial Infarction. 2016 , 12, 31-48		10
298	Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran. 2016 , 356, 305-13		10
297	Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux. <i>Thrombosis Research</i> , 2016 , 141, 17-21	8.2	11

296	Antithrombotic Therapy in Percutaneous Coronary Intervention. 2016 , 5, 239-247	1
295	Traitements antiplaquettaire et anticoagulant des syndromes coronariens aigus. 2016 , 25, 155-167	
294	Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes. 2016 , 33, 233-48	5
293	Anticoagulation in coronary intervention. 2016 , 37, 3376-3385	27
292	Vascular access and antiplatelet therapies: does one influence the other?. 2016 , 37, 1131-2	2
291	Elucidating the use of enoxaparin in non-ST-elevation acute coronary syndromes (NSTEMI-ACS). 2016 , 21, 4-6	2
290	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). 2016 , 37, 267-315.	3850
289	Editor's Choice-Medically managed patients with non-ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease. 2017 , 6, 262-271	9
288	Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis. 2017 , 24, e730-e736	4
287	The epidemic of cardiovascular disease in South Asians: Time for action. 2017 , 185, 150-153	3
286	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. 2017 , 186, 91-99	24
285	Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes. 2017 , 35, 502-507	1
284	Non-ST-Segment Elevation Acute Coronary Syndrome. 2017 , 1-29	1
283	[Management of acute coronary syndrome without ST-segment elevation]. 2017 , 42, 211-228	1
282	Bleeding associated with the management of acute coronary syndromes. 2017 , 103, 546-562	5
281	Duration of dual antiplatelet therapy in acute coronary syndrome. 2017 , 103, 573-580	29
280	A review of strategies for infarct size reduction during acute myocardial infarction. 2017 , 18, 374-383	7
279	Clinical and Economic Impact of a Multidisciplinary Intervention to Reduce Bleeding Risk in Patients With Acute Coronary Syndrome. 2017 , 70, 825-831	1

278	Non-ST Elevation Acute Coronary Syndromes: A Comprehensive Review. 2017 , 42, 266-305	9
277	Management of elderly patients with a non-ST-segment-elevation acute coronary syndrome. 2017 , 25, 409-415	5
276	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. 2017 , 3, 214-220	0
275	Influence of radial versus femoral access site on coronary angiography and intervention outcomes: A systematic review and meta-analysis. 2017 , 90, 1093-1104	20
274	Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case report. 2017 , 5, 342-345	2
273	Análisis de los resultados económicos y en salud de un programa dirigido a la reducción de hemorragia en pacientes con síndrome coronario agudo. 2017 , 70, 825-831	5
272	Antiplatelet therapy in acute coronary syndrome. 2017 , 3, 11-21	1
271	Gender differences in the effects of cardiovascular drugs. 2017 , 3, 163-182	126
270	Renal Dysfunction: How to Think About That in Acute Coronary Syndromes. 2017 , 19, 91	1
269	Challenges in the Design and Interpretation of Noninferiority Trials: Insights From Recent Stent Trials. 2017 , 70, 894-903	15
268	The role of oral anticoagulant therapy in patients with acute coronary syndrome. 2017 , 8, 353-366	13
267	Antithrombotic Therapy for ACS in Elderly Patients. 2017 , 31, 609-618	1
266	[Acute Coronary Syndrome - What should the general practitioner do?]. 2017 , 142, 994-999	0
265	Acute myocardial infarction. 2017 , 389, 197-210	486
264	Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association. 2017 , 6, 34-59	69
263	Milestone 8: Targeting the Xa factor. 2017 ,	3
262	Body mass index and mortality after acute coronary syndromes: a systematic review and meta-analysis. 2017 , 72, 655-661	6
261	Venous thromboembolism: Past, present and future. 2017 , 117, 1219-1229	47

260	Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE). 2017 , 19, D139-D150	3
259	Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pharmacologic pre-treatment for patients undergoing myocardial revascularization procedures. 2017 , 19, D151-D162	0
258	Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review. 2017 , 9, 761-772	2
257	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. 2018 , 29, 469-476	3
256	Acute Coronary Syndromes. 2018 , 197-216	0
255	Trombosis y anticoagulaci3n en la mujer. 2018 , 25, 132-138	
254	Anticoagulation in Acute Coronary Syndrome-State of the Art. 2018 , 60, 508-513	12
253	Optimal treatment of patients with NSTEMI-ACS in the Dutch health care system. 2018 , 26, 289-295	0
252	Coronary Artery Disease in Patients ≥80 Years of Age. 2018 , 71, 2015-2040	81
251	First 24 h in the management of non-ST segment elevation myocardial infarction. 2018 , 20, B29-B38	1
250	Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. 2018 , 13, 1019-1028	1
249	Incidence and predictors of bleeding among Egyptian patients presenting with acute coronary syndrome: Using CRUSADE risk score. 2018 , 70, 135-142	
248	Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-based Review. 2018 , 10, e2114	6
247	Fondaparinux in a critically ill patient with heparin-induced thrombocytopenia: A case report. 2018 , 97, e12236	3
246	Thrombus Pharmacotherapy. 2018 , 587-603	1
245	Continuum of Care for Acute Coronary Syndrome: Optimizing Treatment for ST-Elevation Myocardial Infarction and Non-St-Elevation Acute Coronary Syndrome. 2018 , 17, 114-138	2
244	OBSOLETE: STEMI: Management. 2018 ,	
243	OBSOLETE: Unstable Angina: Presentation, Diagnosis, and Management. 2018 ,	

242	Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention. 2018 , 131, 2417-2423	2
241	Recomendaciones del manejo antiagregante en Cardiología. Documento de revisión de la Sociedad Andaluza de Cardiología. 2018 , 53, e13-e31	
240	Management des akuten Koronarsyndroms. 2018 , 12, 371-390	3
239	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. 2018 , 39, 3766-3776	65
238	Acute Myocardial Infarction: STEMI and NSTEMI. 2018 , 123-146	0
237	Anticoagulant Therapy for Acute Coronary Syndromes. 2018 , 13, 87-92	6
236	Semisynthesis of ent-norstrobane diterpenoids as potential inhibitor for factor Xa. 2018 , 28, 3813-3815	3
235	STEMI: Management. 2018 , 474-488	
234	Antithrombotic Drugs. 2018 , 2168-2188	1
233	Acute Coronary Syndromes. 2018 , 2142-2151.e2	
232	Unstable Angina: Presentation, Diagnosis, and Management. 2018 , 606-615	1
231	2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome. 2018 , 117, 766-790	27
230	Varying Effects of Body Mass Index and Mortality in Different Risk Groups. 2018 , 122, 1155-1160	5
229	Strategies in Acute Coronary Syndrome. 2018 , 921-938	1
228	Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?. 2018 , 118, 1528-1534	3
227	2018 ESC/EACTS Guidelines on myocardial revascularization. 2019 , 40, 87-165	2408
226	2018 ESC/EACTS Guidelines on myocardial revascularization. 2019 , 55, 4-90	251
225	Ischemic Heart Disease in Older Adults. 2019 , 299-299	

224	Extended dual antiplatelet therapy after acute myocardial infarction. Current evidence and future perspectives. 2019 , 89,	1
223	Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes. 2019 , 8, e013032	19
222	. 2019 ,	3596
221	Lost in (Clinical) Translation: Recent Advances in Heparin Neutralization and Monitoring. 2019 , 14, 2512-2526	9
220	Economic evidence. 2019 , 507-523	20
219	Fifty years of research on antithrombotic therapy: Achievements and disappointments. 2019 , 70, 1-7	9
218	Are Ticks the Answer to Medical Device-Associated Clotting?. 2019 , 74, 2190-2192	1
217	From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes: JACC State-of-the-Art Review. 2019 , 74, 1618-1636	17
216	Antithrombotic Agents. 2019 , 124, 426-436	43
215	Dendrigrraft of Poly-l-lysine as a Promising Candidate To Reverse Heparin-based Anticoagulants in Clinical Settings. 2019 , 10, 917-922	9
214	The clinical use of Fondaparinux: A synthetic heparin pentasaccharide. 2019 , 163, 41-53	19
213	Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome. 2019 , 73, 775-778	3
212	Anticoagulant and Antiplatelet Therapy. 2019 , 870-894	2
211	Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review. 2019 , 9, e023337	7
210	Newest Antithrombotic Agents: Uses, Challenges, and Reversal Strategies for Surgical Procedures. 2019 , 481-497	
209	Rivaroxaban for prevention and treatment of venous thromboembolism. 2019 , 15, 63-77	5
208	Anticoagulation in Acute Coronary Syndrome: Review of Major Therapeutic Advances. 2019 , 26, e184-e197	2
207	Anticoagulation in the cardiac patient: A concise review. 2019 , 102, 3-19	5

206	Association of Parenteral Anticoagulation Therapy With Outcomes in Chinese Patients Undergoing Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. 2019 , 179, 186-194	12
205	Treating the troponin: adverse consequences of over-treatment of elevated troponin in non-coronary presentations. 2019 , 64, 10-15	3
204	Perioperative Bleeding in Patients With Acute Coronary Syndrome Treated With Fondaparinux Versus Low-Molecular-Weight Heparin Before Coronary Artery Bypass Grafting. 2019 , 123, 565-570	3
203	Anticoagulation. 2019 , 368-378.e2	1
202	Early anticoagulation in the current management of NSTEMI-ACS: Evidence, guidelines, practice and perspectives. 2019 , 275, 39-45	6
201	Unstable Angina and Non-ST Elevation Myocardial Infarction. 2019 , 233-259	
200	Comparison of CRUSADE and ACUITY-HORIZONS Bleeding Risk Scores in Patients With Acute Coronary Syndromes. 2019 , 28, 567-574	4
199	Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. 2020 , 6, 43-56	16
198	Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry. 2020 , 41, 833-843	36
197	Response to: Antithrombotic therapy for elderly patients with acute coronary syndrome: reasons to be cautious. 2020 , 6, 70	
196	Transradial Angiography and Intervention in Acute Coronary Syndromes. 2020 , 9, 33-40	
195	Radial artery access is associated with lower mortality in patients undergoing primary PCI: a report from the SWEDEHEART registry. 2020 , 9, 323-332	3
194	Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis: A Systematic Review. 2020 , 5, 1286-1297	
193	Antithrombotic Therapy in Myocardial Infarction: Historic Perils and Current Challenges-A 70-Year Journey. 2020 , 120, 1352-1356	3
192	Antithrombotic PreTreatment and Invasive Strategies in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. 2020 , 9,	1
191	Optimal P2Y12 inhibition in older adults with acute coronary syndromes: A network meta-analysis of randomized controlled trials. 2020 ,	5
190	Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics. 2020 , 21, 2595-2621	1
189	Anti-Factor Xa Activity of Fixed-Dose Fondaparinux in Low-Body-Weight Patients With Acute Coronary Syndrome. 2020 , 54, 1083-1089	

188	Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. 2020 , 9,	1
187	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020 , 383, e8	59.2 5
186	New Antithrombotic Drugs in Acute Coronary Syndrome. 2020 , 9,	9
185	Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154'000 Individuals. 2020 , 9, e014686	24
184	Smoking and antiplatelet therapy after acute coronary syndromes. 2020 , 6, 382-383	
183	Treatment of thrombosis. 2020 , 105-144	
182	Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC. 2020 , 9, 59-81	31
181	Pharmacology before, during and after percutaneous coronary intervention. 2020 ,	1
180	How cardiologists manage antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary stenting: the WOEST survey 2018. 2021 , 29, 135-141	0
179	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. 2021 , 42, 1289-1367	920
178	Cardiovascular Medications. 2021 , 597-642	1
177	Fondaparinux Pre-, Peri-, and/or Postpartum for the Prophylaxis/Treatment of Venous Thromboembolism (FondaPPP). 2021 , 27, 10760296211014575	3
176	Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention. 2021 , 29, 119-120	
175	Das akute Koronarsyndrom in der prähospitalen Phase und in der Notaufnahme. 2021 , 24, 1055	
174	Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. 2021 , 20, 2847	1
173	2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. 2021 , 26, 4449	22
172	Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. 2021 , 74, 544.e1-544.e73	1
171	2020 Russian and European clinical practice guidelines for the management of NSTEMI patients: have approaches to antithrombotic therapy been simplified?. 2021 , 10, 92-101	

170	Fondaparinux versus enoxaparin in the contemporary management of non-ST-elevation acute coronary syndromes. Insights from a multicenter registry. 2021 , 332, 29-34	2
169	Consolidating the value of fondaparinux for current treatment of non-ST-elevation acute coronary syndromes. 2021 , 335, 21-23	1
168	Anticoagulation in ST-Elevation Myocardial Infarction. 2021 , 10, 307-316	0
167	Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. 2021 , 8,	0
166	Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021. 2021 , 117, 181-264	7
165	Contemporary use of anticoagulation in the cardiac catheterization laboratory: a review. 2021 ,	
164	Fondaparinux During Intra-Aortic Balloon Pump Counterpulsation in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. 2021 , 30, 1545-1551	
163	Non-ST-Elevation Acute Coronary Syndromes. 2022 , 413-428	
162	Gender differences in anticoagulation and antithrombotic therapy. 2012 , 523-42	8
161	Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes: European Society of Cardiology Guidelines. 2011 , 369-384	2
160	ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction—Summary Article. 2011 , 385-404	2
159	Unstable Angina and Non-ST Elevation Myocardial Infarction. 2012 , 1178-1209	5
158	Percutaneous Coronary Intervention. 2012 , 1270-1300	3
157	Anticoagulant activity and pleiotropic effects of heparin. 2020 , 45, 147-157	3
156	Acute coronary syndromes: diagnosis and management, part I. 2009 , 84, 917-38	111
155	Una historia resumida. Impacto de los avances en cardiopatía isquémica. 2017 , 17, 2-6	1
154	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. 2021 , 42, 339-351	24
153	Acute Coronary Syndromes. 2009 , 535-596	9

152	Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions. 2014 , 9, 94-101	2
151	Major Bleeding and Adverse Outcome following Percutaneous Coronary Intervention. 2015 , 10, 22-25	5
150	Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. 2006 , 2, 371-8	2
149	Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome. 2007 , 3, 221-8	2
148	Emerging Anticoagulants and Heparin-Induced Thrombocytopenia: Indirect and Direct Factor Xa Inhibitors and Oral Thrombin Inhibitors. 2007 , 441-462	5
147	Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. 2009 , 5, 325-9	120
146	Prognostic impact of major bleeding in patients with acute coronary syndromes.A systematic review and meta-analysis. 2007 , 3, 400-8	29
145	Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS). 2010 , 6, 407-12	3
144	Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. 2011 , 7, 91-7	41
143	Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study. 2012 , 8, 486-92	1
142	The transradial versus the transfemoral approach for primary percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis. 2012 , 8, 501-10	58
141	A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. 2013 , 8, 1052-60	45
140	Full conversion from transfemoral to transradial approach for percutaneous coronary interventions results in a similar success rate and a rapid reduction of in-hospital cardiac and vascular major events. 2013 , 9, 345-52	12
139	Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. 2014 , 10, 431-8	22
138	2014 ESC/EACTS guidelines on myocardial revascularization. 2015 , 10, 1024-94	195
137	2018 ESC/EACTS Guidelines on myocardial revascularization. 2019 , 14, 1435-1534	180
136	Hemostatic Aspects of Cardiovascular Medicine. 2007 , 339-369	
135	Anti-thrombin therapy. 2008 , 45-53	

- 134 Medicamenteuze preventie en behandeling van atherotrombose. **2008**, 89-101
- 133 Controversies and future approaches. **2008**, 69-76
- 132 Traitement de l'angor stable et des syndromes coronariens aigus sans sus-décalage du segment ST. **2008**, 73-100
- 131 The Future of Reperfusion Therapy. **2008**, 316-332
- 130 Anti-thrombin therapy. **2009**, 49-59
- 129 Controversies and future approaches. **2009**, 79-88
- 128 Bias in AJHP supplements. **2008**, 65, 2329-2330
- 127 ACC/AHA Non-ST Elevation Myocardial Infarction Guidelines' Revision 2007: Implications for Nursing Practice. **2008**, 23, 53-56
- 126 Medical Therapy in Patients Managed in a Chest Pain Observation Unit. **2009**, 147-153
- 125 Acute cardiac syndromes, investigations and interventions. **2009**, 155-177
- 124 Akute Koronarsyndrome. **2009**, 429-468
- 123 Pharmacological Support. **2009**, 93-109
- 122 Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. **2009**, 293-340
- 121 Anticoagulants for the Treatment of Venous Thromboembolism. **2009**, 155-170
- 120 Oral Direct Factor Xa Inhibitors. **2009**, 307-326
- 119 Anticoagulants in Cancer. **2009**, 221-236
- 118 New Heparins: Synthetic Pentasaccharides. **2009**, 253-268
- 117 Anticoagulation in Acute Coronary Syndromes. **2009**, 171-196

116 Synthetic Factor Xa Inhibition in Acute Coronary Syndromes. **2010**, 203-215

115 Unfractionated Heparin and Enoxaparin for the Management of Non-ST-Segment Elevation Acute Coronary Syndromes. **2010**, 165-181

114 Antithrombotic Therapy in Percutaneous Coronary Intervention. **2010**, 261-282

113 Acute coronary syndromes without persistent ST elevation in the light of the 2007 and 2008 guidelines. **2009**, 51, 48-51

112 Acute Coronary Syndrome. **2010**, 947-983

111 Anticoagulant Therapy. **2010**, 126-129

110 Antithrombotic Agents. **2010**, 541-555

109 Acute Coronary Syndromes. **2010**, 1026-1059

108 Antikoagulation. **2010**, 749-794

107 Acute Coronary Syndromes. 1-22

106 Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention. **2010**, 240-249

105 Cardiology. 185-193

104 Pharmacology in the Cardiac Catheterization Laboratory. 428-447

103 Unstable Angina and Non-ST Elevation Myocardial Infarction. **2011**, 195-225

102 Management of non-ST-elevation acute coronary syndromes. **2011**, 485-495

101 Percutaneous coronary intervention. **2011**, 434-443

100 Intravenous heparin, low-molecular-weight heparins, and thrombin antagonists. **2011**, 297-306

99 Thrombolytics/Anticoagulants. **2011**, 1-67

- 98 Bleeding in the Acute Coronary Syndromes. **2011**, 322-329
- 97 Almanac 2011: Acute Coronary Syndromes. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology. **2011**, 23, 161-70
- 96 Acute coronary syndromes. **2011**, 459-467
- 95 Bleeding complications and transfusion in acute coronary syndrome. **2011**, 633-640
- 94 Percutaneous Coronary Intervention and Concomitant Antithrombotic Therapy. **2011**, 313-321
- 93 Heparin, LMWH, GIIb/IIIa, and Direct Thrombin Inhibitors. 110-143
- 92 Indications in Acute Coronary Syndromes without ST Elevation (NSTEMI-ACS). 232-241
- 91 Antithrombotic Therapy for Non-ST-Elevation Acute Coronary Syndrome. 223-240
- 90 Risque hémorragique et syndromes coronariens aigus chez les sujets âgés. **2011**, 195, 1981-1987
- 89 Thrombolytic Intervention. **2012**, 142-158
- 88 Acute coronary syndromes. **2012**, 31, 90-99
- 87 Medical Economics in Interventional Cardiology. **2012**, 861-876
- 86 Intervention for Non-ST-Segment Elevation Acute Coronary Syndromes. **2012**, 223-236
- 85 Diabetes. **2012**, 30-49
- 84 Anticoagulation in Percutaneous Coronary Intervention. **2012**, 113-125
- 83 Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease. **2012**, 1844-1867
- 82 Cardiovascular Disease in Women. **2012**, 1757-1769
- 81 Antithrombotic therapies. **2012**, 44-66

- 80 How should I treat a "swinging" left main thrombosis complicating coronary angioplasty in an obese, diabetic, elderly woman treated with fondaparinux?. **2012**, 7, 1470-5
- 79 Acute coronary syndromes: is there a place for a real pre-hospital treatment for patients "en route" to the coronary intensive care unit?. **2012**, 8 Suppl P, P36-43
- 78 Antithrombotic pharmacotherapy in patients with established coronary artery disease. **2012**, 287-301
- 77 Antithrombotic Therapy in NonâST-Segment Elevation Acute Coronary Syndromes. 213-235
- 76 Acute coronary syndromes. **2012**, 34-57
- 75 Kardiologische Therapie bei Hochbetagten. **2013**, 433-446
- 74 Examining access routes and bleeding risk in women undergoing percutaneous coronary intervention. **2013**, 5, 419-425
- 73 Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors. **2014**, 59-122
- 72 Acute Coronary Syndromes. **2014**, 15-36
- 71 Anesthetic Considerations: Open Versus Minimally Invasive Surgery. **2014**, 31-48
- 70 Antithrombotic Issues in Women. **2014**, 321-357
- 69 Interventional Management of Coronary Artery Disease: Acute Coronary Syndromes. **2014**, 1-43
- 68 Medical Management of Coronary Artery Disease. **2014**, 1-17
- 67 Thrombosis in Diabetes and Its Clinical Management. 185-214
- 66 Medical Management of Coronary Artery Disease. **2015**, 2369-2382
- 65 Interventional Management of Coronary Artery Disease: Acute Coronary Syndromes. **2015**, 2071-2107
- 64 Radial and Femoral Access in Percutaneous Intervention. **2015**, 361-371
- 63 Prognosis of Patients with Acute Coronary Syndromes and BleedingâThe Importance of Routine Use of a Bleeding Risk Score. **2015**, 05, 327-334

- 62 Peri- and Post-procedural Antithrombotic Therapy in Women. **2017**, 73-100 0
- 61 Treatment of Acute Coronary Syndromes in Elderly Patients. **2017**, 165-177
- 60 Traitement de l'angor stable et des syndromes coronariens aigus sans sus-décalage du segment ST. **2018**, 75-98.e1
- 59 Coronary Intervention in the Chronic Kidney Disease, Diabetic and Elderly Populations. **2018**, 291-303
- 58 Acute coronary syndrome in elderly: aspects of patient management. **2019**, 13, 19-26 3
- 57 Comparison in Terms of Safety and Efficacy between Fondaparinux and Enoxaparin in Acute Coronary Syndrome. **2019**, 8, 2519-2522
- 56 Coagulation and Anticoagulants. **2020**, 1-53
- 55 Anticoagulation in Patients with Renal Insufficiency. **2020**, 203-238
- 54 Advances in the Application of Fondaparinux in Acute Coronary Syndrome. **2020**, 09, 201-207
- 53 A tetracationic aggregation induced emission-based probe for efficient and improved detection of Heparin. *Sensors and Actuators B: Chemical*, **2021**, 353, 131016 8,5 1
- 52 Unstable Angina/Non-ST Elevation Myocardial Infarction. **2020**, 99-110
- 51 Heparin-Induced Thrombocytopenia. **2008**, 205-238
- 50 Management of Acute Myocardial Infarction. **2007**, 183-210
- 49 Antiplatelet Agents, Anticoagulants, and Specific Thrombin Inhibitors. **2007**, 331-348
- 48 Hallmark Clinical Trials. **2007**, 381-394
- 47 Administraci3n upstream de inhibidores de la glucoprote3na IIb/IIIa en el s3ndrome coronario agudo sin elevaci3n del segmento ST: la estrategia TACTICS. **2011**, 11, 27-32
- 46 Management of acute coronary syndromes with fondaparinux. **2007**, 3, 321-9 10
- 45 Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. **2009**, 101, 878-85 10

44	Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). 2010 , 37, 262-75		9
43	A novel treatment of refractory coronary embolism: thrombus aspiration catheter-assisted twisting wire technique. 2020 , 17, 110-115		1
42	Heparin use in acute coronary syndromes and cardiovascular interventions: habit or evidence based?. 2022 ,		0
41	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2021 ,		42
40	Non-ST-Segment Elevation Acute Coronary Syndrome. 2022 , 1-37		
39	Das akute Koronarsyndrom in der prähospitalen Phase und in der Notaufnahme. 2022 , 16, 61-68		
38	Fondaparinux: A cornerstone drug in acute coronary syndromes.. 2022 , 14, 40-53		0
37	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2021 , CIR0000000000001038		23
36	When and How to Combine Antiplatelet and Anticoagulant Drugs?. 2022 , 42, 73-79		0
35	Periprocedural Antithrombotic Treatment in Complex Percutaneous Coronary Intervention.. 2022 , 79, 407-419		0
34	Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 234, 114256	6.8	2
33	A highly efficient and selective optical detection method for Heparin that works in 100% human serum. <i>Sensors and Actuators B: Chemical</i> , 2022 , 359, 131613	8.5	0
32	Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study.. <i>Thrombosis Research</i> , 2022 , 213, 57-64	8.2	0
31	Porous Polymers as Universal Reversal Agents for Heparin Anticoagulants through an Inclusion-Sequestration Mechanism.. <i>Advanced Materials</i> , 2022 , e2200549	24	1
30	Monitoring and Reversal of Anticoagulation and Antiplatelet Agents. 2022 , 491-502		
29	Parenteral Anticoagulant Agents in PCI. 2022 , 439-445		
28	Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease. 2022 , 407-419		
27	Anticoagulants: dose control methods and inhibitors. <i>Obstetrics, Gynecology and Reproduction</i> , 2022 , 16, 158-175	0.5	0

26	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. 2013 , 332-397		1
25	Das akute Koronarsyndrom in der prähospitalen Phase und in der Notaufnahme.		
24	Parenteral anticoagulants in the treatment of acute coronary syndrome: what modern clinical guidelines say. <i>Atherothrombosis</i> , 2022 , 12, 46-58	0.3	
23	The Evolution of Anticoagulation for Percutaneous Coronary Intervention:A 40-Year Journey. <i>Canadian Journal of Cardiology</i> , 2022 ,	3.8	0
22	Choosing Between Enoxaparin and Fondaparinux for the Prevention of Thromboembolism: A Meta-Analysis of Randomized Trials. <i>Egyptian Journal of Critical Care Medicine</i> , 2022 , 9, 22-30	0	
21	Evidence gaps pertaining to high-risk medications - Commentary on anticoagulation in new onset postoperative atrial fibrillation. <i>Heart Rhythm O2</i> , 2022 ,	1.5	
20	Chemoenzymatic Synthesis of Genetically-Encoded Multivalent Liquid N-glycan Arrays.		
19	Epidemiology, Pathophysiology, and Management of Coronary Artery Disease in the Elderly.		0
18	Medical Therapy in Patients Managed in a Chest Pain Observation Unit. 2022 , 127-133		0
17	Epidemiological Characteristics and Risk Factors Associated with Acute Myocardial Infarction in Somalia: A Single-Center Experience. Volume 15, 7605-7617		0
16	Chemoenzymatic Synthesis of Genetically-Encoded Multivalent Liquid N-glycan Arrays.		0
15	Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome. 2022 , 11, 5605		0
14	THE ACUTE CORONARY SYNDROME : POSSIBILITY ON THE MODERN THERAPY (literature review. Part II). 2010 , 13-19		0
13	Real-World Registry Study Confirms Fondaparinux Over Low-Molecular-Weight Heparin for NSTEMI. 89-93		0
12	Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction â€”REGION-IM. 2022 , 62, 3-15		0
11	Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects. 12,		1
10	Acute, periprocedural and longterm antithrombotic therapy in older adults.		0
9	Adjunctive Pharmacologic Agents and Mechanical Devices in Primary Percutaneous Coronary Intervention. 2010 , 39, 230-236		0

- 8 Clinical Studies with Anticoagulants that Have Changed Clinical Practice. ○
- 7 Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. **2023**, 28, 107424842211450 ○
- 6 Acute Coronary Syndrome in the Older Adult Populations. **2023**, 303-341 ○
- 5 Acute Coronary Syndrome. **2013**, 452-468.e1 ○
- 4 Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. **2023**, 24, 453-471 ○
- 3 Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome. **2023**, 6, e2255709 ○
- 2 Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India. ○
- 1 Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome. **2023**, 23, ○